Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, United States; Department of Neurology, University of North Carolina, Chapel Hill, United States
UNC Neuroscience Center, University of North Carolina, Chapel Hill, United States; Carolina Institute for Developmental Disabilities, University of North Carolina, Chapel Hill, United States; Department of Genetics, University of North Carolina, Chapel Hill, United States
Baggio A Evangelista
Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, United States; Department of Neurology, University of North Carolina, Chapel Hill, United States
Youjun Chen
Department of Neurology, University of North Carolina, Chapel Hill, United States
Xu Tian
Department of Neurology, University of North Carolina, Chapel Hill, United States
Sara Nafees
Department of Neurology, University of North Carolina, Chapel Hill, United States
Ariana B Marquez
Human Pluripotent Stem Cell Core, University of North Carolina, Chapel Hill, United States
Huijun Jiang
Department of Biostatistics, University of North Carolina, Chapel Hill, United States
Ping Wang
Department of Neurology, University of North Carolina, Chapel Hill, United States
Deepa Ajit
Department of Neurology, University of North Carolina, Chapel Hill, United States
Viktoriya D Nikolova
Carolina Institute for Developmental Disabilities, University of North Carolina, Chapel Hill, United States; Department of Psychiatry, The University of North Carolina, Chapel Hill, United States
Carolina Institute for Developmental Disabilities, University of North Carolina, Chapel Hill, United States; Department of Psychiatry, The University of North Carolina, Chapel Hill, United States
Department of Cell Biology & Physiology, Histology Research Core Facility, University of North Carolina, Chapel Hill, United States
Feng-Chang Lin
Department of Biostatistics, University of North Carolina, Chapel Hill, United States
Adriana S Beltran
Department of Genetics, University of North Carolina, Chapel Hill, United States; Human Pluripotent Stem Cell Core, University of North Carolina, Chapel Hill, United States; Department of Pharmacology, University of North Carolina, Chapel Hill, United States
Sheryl S Moy
Carolina Institute for Developmental Disabilities, University of North Carolina, Chapel Hill, United States; Department of Psychiatry, The University of North Carolina, Chapel Hill, United States
Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, United States; Department of Neurology, University of North Carolina, Chapel Hill, United States; UNC Neuroscience Center, University of North Carolina, Chapel Hill, United States; Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, United States
TDP-43 proteinopathies including frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative disorders characterized by aggregation and mislocalization of the nucleic acid-binding protein TDP-43 and subsequent neuronal dysfunction. Here, we developed endogenous models of sporadic TDP-43 proteinopathy based on the principle that disease-associated TDP-43 acetylation at lysine 145 (K145) alters TDP-43 conformation, impairs RNA-binding capacity, and induces downstream mis-regulation of target genes. Expression of acetylation-mimic TDP-43K145Q resulted in stress-induced nuclear TDP-43 foci and loss of TDP-43 function in primary mouse and human-induced pluripotent stem cell (hiPSC)-derived cortical neurons. Mice harboring the TDP-43K145Q mutation recapitulated key hallmarks of FTLD, including progressive TDP-43 phosphorylation and insolubility, TDP-43 mis-localization, transcriptomic and splicing alterations, and cognitive dysfunction. Our study supports a model in which TDP-43 acetylation drives neuronal dysfunction and cognitive decline through aberrant splicing and transcription of critical genes that regulate synaptic plasticity and stress response signaling. The neurodegenerative cascade initiated by TDP-43 acetylation recapitulates many aspects of human FTLD and provides a new paradigm to further interrogate TDP-43 proteinopathies.